OBJECTIVES: The purpose of this study was to evaluate complement activation in a heart failure cohort. Based on their powerful biological activity, we hypothesized that the levels of anaphylatoxin C3a are related to pathological signs and outcomes in heart failure. DESIGN, SETTING AND PATIENTS: Complement activation products C3a and SC5b9 were determined in 182 consecutive CHF patients (single centre, prospective cohort study), with a left ventricular ejection fraction <45%. Mortality and re-hospitalisation due to the progression of CHF were assessed after a median follow-up of 14 months. INTERVENTIONS: None. RESULTS: In the univariate analysis, high level of anaphylatoxin C3a was significantly associated with clinical events (p < 0.0001), whereas SC5b9 showed a tendency of association (p = 0.094). In multivariable Cox analysis, adjusted for age, NT-proBNP, diastolic blood pressure, body mass index (BMI), haemoglobin and creatinine levels, C3a was a significant predictor of HF-related re-hospitalization or death (HR 1.189 per 1-SD increase, 95% CI 1.023-1.383), and of cardiovascular events or death (HR 1.302, CI 1.083-1.566). C3a was strongly associated with the presence of peripheral oedema, inflammatory markers (CRP, prealbumin, IL-6, sTNFRI, sTNFRII), heat-shock protein 70 levels and endothelial activation markers (von-Willebrand factor and endothelin-1). CONCLUSIONS: Results of the present study showed that complement activation is strongly linked to unfavourable outcomes in heart failure. High levels of anaphylatoxin C3a predicted re-hospitalization, cardiovascular events and mortality in adjusted survival model. Increased C3a levels were associated with biomarkers of acute-phase reaction, inflammation, cellular stress response, endothelial-cell activation and oedematous complications independently from disease severity.
OBJECTIVES: The purpose of this study was to evaluate complement activation in a heart failure cohort. Based on their powerful biological activity, we hypothesized that the levels of anaphylatoxin C3a are related to pathological signs and outcomes in heart failure. DESIGN, SETTING AND PATIENTS: Complement activation products C3a and SC5b9 were determined in 182 consecutive CHFpatients (single centre, prospective cohort study), with a left ventricular ejection fraction <45%. Mortality and re-hospitalisation due to the progression of CHF were assessed after a median follow-up of 14 months. INTERVENTIONS: None. RESULTS: In the univariate analysis, high level of anaphylatoxin C3a was significantly associated with clinical events (p < 0.0001), whereas SC5b9 showed a tendency of association (p = 0.094). In multivariable Cox analysis, adjusted for age, NT-proBNP, diastolic blood pressure, body mass index (BMI), haemoglobin and creatinine levels, C3a was a significant predictor of HF-related re-hospitalization or death (HR 1.189 per 1-SD increase, 95% CI 1.023-1.383), and of cardiovascular events or death (HR 1.302, CI 1.083-1.566). C3a was strongly associated with the presence of peripheral oedema, inflammatory markers (CRP, prealbumin, IL-6, sTNFRI, sTNFRII), heat-shock protein 70 levels and endothelial activation markers (von-Willebrand factor and endothelin-1). CONCLUSIONS: Results of the present study showed that complement activation is strongly linked to unfavourable outcomes in heart failure. High levels of anaphylatoxin C3a predicted re-hospitalization, cardiovascular events and mortality in adjusted survival model. Increased C3a levels were associated with biomarkers of acute-phase reaction, inflammation, cellular stress response, endothelial-cell activation and oedematous complications independently from disease severity.
Authors: D J Clark; M W Cleman; S E Pfau; S A Rollins; T M Ramahi; C Mayer; T Caulin-Glaser; E Daher; M Kosiborod; L Bell; J F Setaro Journal: Am Heart J Date: 2001-04 Impact factor: 4.749
Authors: Jana Papassotiriou; Nils G Morgenthaler; Joachim Struck; Christine Alonso; Andreas Bergmann Journal: Clin Chem Date: 2006-04-20 Impact factor: 8.327
Authors: J Niebauer; H D Volk; M Kemp; M Dominguez; R R Schumann; M Rauchhaus; P A Poole-Wilson; A J Coats; S D Anker Journal: Lancet Date: 1999-05-29 Impact factor: 79.321
Authors: C D Collard; A Väkevä; M A Morrissey; A Agah; S A Rollins; W R Reenstra; J A Buras; S Meri; G L Stahl Journal: Am J Pathol Date: 2000-05 Impact factor: 4.307
Authors: Sabine Genth-Zotz; Aidan P Bolger; Paul R Kalra; Stephan von Haehling; Wolfram Doehner; Andrew J S Coats; Hans-Dieter Volk; Stefan D Anker Journal: Int J Cardiol Date: 2004-09 Impact factor: 4.164
Authors: C Suffritti; E Tobaldini; R Schiavon; S Strada; L Maggioni; S Mehta; G Sandrone; E Toschi-Dias; M Cicardi; N Montano Journal: Clin Exp Immunol Date: 2017-08-04 Impact factor: 4.330
Authors: Gábor Széplaki; András Mihály Boros; Szabolcs Szilágyi; István Osztheimer; Zsigmond Jenei; Annamária Kosztin; Klaudia Vivien Nagy; Júlia Karády; Levente Molnár; Tamás Tahin; Endre Zima; László Gellér; Zoltán Prohászka; Béla Merkely Journal: Inflamm Res Date: 2016-08-04 Impact factor: 4.575
Authors: Petri O Tuomainen; Jarkko Magga; Pekka Timonen; Kati Miettinen; Minna Kurttila; Esko Vanninen; Tomi Laitinen; Kirsi Timonen; Kari Punnonen; Ilkka Parviainen; Ari Uusaro; Olli Vuolteenaho; Matti Kivikko; Keijo Peuhkurinen Journal: Clin Res Cardiol Date: 2013-03-17 Impact factor: 5.460
Authors: Jean F Regal; Jenna M Lund; Cameron R Wing; Kate M Root; Luke McCutcheon; Lynne T Bemis; Jeffrey S Gilbert; Sherry D Fleming Journal: Mol Immunol Date: 2019-07-18 Impact factor: 4.407
Authors: Hilde L Orrem; Per H Nilsson; Søren E Pischke; Guro Grindheim; Peter Garred; Ingebjørg Seljeflot; Trygve Husebye; Pål Aukrust; Arne Yndestad; Geir Ø Andersen; Andreas Barratt-Due; Tom E Mollnes Journal: ESC Heart Fail Date: 2018-02-09
Authors: Zoltán Prohászka; Lea Munthe-Fog; Thor Ueland; Timea Gombos; Arne Yndestad; Zsolt Förhécz; Mikkel-Ole Skjoedt; Zoltan Pozsonyi; Alice Gustavsen; Lívia Jánoskuti; István Karádi; Lars Gullestad; Christen P Dahl; Erik T Askevold; George Füst; Pål Aukrust; Tom E Mollnes; Peter Garred Journal: PLoS One Date: 2013-04-15 Impact factor: 3.240
Authors: Sylwia Wasiak; Dean Gilham; Laura M Tsujikawa; Christopher Halliday; Cyrus Calosing; Ravi Jahagirdar; Jan Johansson; Michael Sweeney; Norman C Wong; Ewelina Kulikowski Journal: J Cardiovasc Transl Res Date: 2017-05-31 Impact factor: 4.132